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Abstract
Background—Retention in care is important for all HIV-infected persons and is strongly 
associated with initiation of antiretroviral therapy and viral suppression. However, it is unclear 
how retention in care and age interact to effect viral suppression. We evaluated whether the 
association between retention and viral suppression differed by age at entry into care.
Methods—Cross-sectional analysis (2006-2010) involving 17,044 HIV-infected adults in 14 
clinical cohorts across the U.S. and Canada. Patients contributed one year of data during their first 
full calendar year of clinical observation. Poisson regression examined associations between 
retention measures [U.S. National HIV/AIDS Strategy (NHAS), U.S. Department of Health and 
Human Services (DHHS), 6-month gap, and 3-month visit constancy] and viral suppression (HIV 
RNA ≤200 copies/mL) by age group: 18-29, 30-39, 40–49, 50–59, and ≥60 years old.
Results—Overall, 89% of patients were retained in care using the NHAS measure, 74% with the 
DHHS indicator, 85% did not have a 6-month gap, and 62% had visits in 3-4 quarters of the year; 
54% achieved viral suppression. For each retention measure, the association with viral suppression 
was significant for only the younger age groups (18-29 and 30-39 years): 18-29 [adjusted 
prevalence ratio (APR)=1.33, 95% confidence interval (CI)=1.03-1.70]; 30-39 (APR=1.23, 
CI=1.01-1.49); 40-49 (APR=1.06, CI=0.90-1.22); 50-59 (APR=0.92, CI=0.75-1.13); ≥60 years 
(APR=0.99, CI=0.63-1.56) using the NHAS measure as a representative example.
Conclusions—These results have important implications for improving viral control among 
younger adults, emphasizing the crucial role retention in care plays in supporting viral suppression 
in this population.
Keywords
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Introduction
HIV-infected persons must complete several steps along a care continuum – HIV testing and 
diagnosis, linkage to and retention in primary HIV care, and receipt and adherence to 
antiretroviral therapy (ART) – to optimize individual and public health outcomes.1,2 
Yehia et al. Page 2






















Retention in care is a key step in this process, associated with initiation of ART, decreased 
mortality, and reduced HIV transmission to others.3-12
Multiple surveillance and cohort studies indicate that both patients’ age and retention in 
care status may impact HIV viral suppression.13-22 Among 35,433 HIV-infected adults 
followed at 18 primary and specialty care clinics in the United States (U.S.) between 2006 
and 2011, older individuals and those retained in care were more likely to achieve viral 
suppression than younger persons and those poorly engaged in care, respectively.15 
Similarly, of 338,959 persons living with HIV in 19 U.S. jurisdictions in 2010, older age and 
retention in care were both significantly associated with viral suppression.19
However, it is unclear how retention in care and age interact to effect viral suppression. 
Retention in care may enhance medication adherence in younger adults, who are reported to 
have lower rates of ART compliance compared to older populations.23-26 Alternatively, 
consistent engagement in care may support ART adherence in older individuals by 
minimizing drug-drug interactions and treating comorbid conditions.27,28 Gaining a better 
understanding of the relationships between retention in care, age, and viral suppression may 
assist in designing interventions to improve HIV care and outcomes. We used data from a 
multisite cohort collaboration to evaluate whether the association between retention in care 
and viral suppression varied by age at entry into care.
Methods
Study Design and Population
We conducted a cross-sectional analysis from 2006-2010 using data from the North 
American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), a multisite 
collaboration of cohort studies of HIV-infected adults (age ≥18 years) receiving care in the 
U.S. and Canada. NA-ACCORD is one of the multinational cohort studies sponsored by the 
International Epidemiological Databases to Evaluate AIDS consortium of the National 
Institutes of Health. Details on the NA-ACCORD collaboration have been published 
previously.29 Briefly, contributing cohorts have standardized cohort-specific methods of 
data collection. At scheduled intervals, investigators at these cohorts submit data regarding 
participants’ demographic characteristics, ART prescription information, dates and results of 
laboratory tests including HIV-1 RNA and CD4 count, clinical diagnoses, and vital status. 
These data are transferred securely to the NA-ACCORD central Data Management Core, 
where they undergo quality control for completeness and accuracy before they are combined 
into harmonized data files. The activities of the NA-ACCORD have been reviewed and 
approved by the local institutional review boards for each site and at Johns Hopkins School 
of Medicine.
Data from 14 NA-ACCORD clinical cohorts, with participants residing in all 50 U.S. states, 
the District of Columbia, Puerto Rico, and 10 Canadian provinces and territories, were 
included in analyses. HIV-infected adults (age ≥18 years) newly enrolled in care at these 
NA-ACCORD sites (i.e. first visit to these sites) between January 1, 2006 and December 
31, 2010 were eligible for inclusion.30 To assure exclusion of those who may have received 
care previously (e.g. transferring care from a clinic outside the NA-ACCORD to an NA-
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ACCORD site), we excluded patients with first recorded HIV-1 RNA ≤ 200 copies/mL and 
individuals with ART use prior to NA-ACCORD enrollment. Interval cohort studies that 
participate in NA-ACCORD were excluded from this analysis because of our focus on the 
nature of HIV care in the U.S. and Canada.31
Retention Measures
Since multiple measures of retention in care are currently in use, with no clear gold 
standard,13,32 we applied four commonly used measures of retention for each patient in their 
first full calendar year of observation (subsequent to their year of entry at an NA-ACCORD 
site) to describe their pattern of attendance at primary HIV care visits. For some patients this 
also represented their first full calendar year after initial HIV diagnosis. The use of the first 
full calendar year reflects the common practice of measuring retention in care on a calendar 
year basis.32
First, the U.S. National HIV/AIDS Strategy (NHAS) retention in care measure 
dichotomously defines retention as having 2 or more HIV visits separated by ≥ 90 days 
during a calendar year.33 Second, the U.S. Department of Health and Human Services 
(DHHS) retention in HIV care indicator defines retention as having ≥ 1 HIV visits in each 
half of the calendar year (Jan-Jun and Jul-Dec), at least 60 days apart.34 Third, the 6- month 
gap in care measure reflects whether a patient had ≥ 6 months between sequential outpatient 
visits, with no gap signifying retention in care. Fourth, 3-month visit constancy, an ordinal 
measure, is the number of 3-month intervals in a calendar year in which a patient completes 
at least 1 HIV visit (range, 1-4). For all four measures evaluated in this study, HIV visits 
refer only to completed primary HIV care appointments at NA-ACCORD clinics and do not 
include nursing, pharmacy, laboratory, social services, or other types of visits.
Each retention measure has its particular advantages and limitations.13,32,35 Constancy 
measures, such as the NHAS measure, DHHS indicator, 3-month visit constancy measure, 
and the 6-month gap in care measure, do not require scheduled and missed visit data to be 
calculated; data elements which are not always readily available. The NHAS measure and 
DHHS indicator are unique in that several federal programs utilize them to monitor HIV 
outcomes. However, they may overestimate retention for patients needing more frequent 
visits. Conversely, the 3-month visit constancy measure is at risk of underestimating 
retention for patients needing less frequent monitoring. The 6-month gap in care measure is 
able to capture long breaks between visits, but may be difficult to calculate when there is no 
recently attended visit. Multiple studies have compared different measures of retention in 
care, demonstrating moderate to strong correlation between measures and modest 
discrimination for viral suppression.13,15,32,36
Outcome Variable
HIV viral suppression was the outcome of interest, defined by the U.S. Health Resources 
and Services Administration (HRSA) HIV/AIDS Bureau HIV viral load suppression 
performance measure.37 Persons were categorized as suppressed (HIV-1 RNA ≤ 200 
copies/mL) and not suppressed (HIV-1 RNA > 200 copies/mL) using the last HIV-1 RNA 
value reported in the calendar year. Those with missing HIV-1 RNA values (10% of the 
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sample) were excluded from regression analyses; sensitivity analyses were conducted 
classifying these individuals as “not suppressed.”38
Sociodemographic and Clinical Variables
Patients’ age as of January 1 of the calendar year was divided into five groups: 18-29, 30-39, 
40–49, 50–59, and ≥ 60 years old. Race/ethnicity was categorized as non-Hispanic White, 
non-Hispanic Black, Hispanic, and other/unknown. HIV transmission risk factor was 
grouped into men who had sex with men (MSM), heterosexual transmission (HET), 
injection drug use (IDU), and other/unknown. Patients who had IDU in combination with 
another risk factor (e.g. MSM, HET) were classified as IDU. Patients were considered to be 
on ART if they concomitantly were prescribed ≥ 3 antiretroviral drugs from at least 2 classes 
or triple nucleoside/nucleotide reverse transcriptase inhibitor regimen containing abacavir or 
tenofovir for at least 6 months during the calendar year. First CD4 count recorded in the 
calendar year was grouped as < 350, 350-499, or ≥ 500 cells/mm3.
Statistical Analyses
Standard descriptive analyses of demographic and clinical characteristics of the sample were 
conducted. Chi-squared tests for differences in proportion were used to detect unadjusted 
differences in viral suppression status by age group, within retention strata. Multivariable 
Poisson regression models with robust variance were used to estimate adjusted prevalence 
ratios (APR) and 95% confidence intervals of the association between each measure of 
retention and viral suppression, adjusting for age group, gender, race/ethnicity, HIV 
transmission risk factor, use of ART, first CD4 count, calendar year, and cohort. Covariates 
were selected a priori based on a literature review of factors influencing retention in care 
and viral suppression.13-18 Insurance status was not uniformly collected by NA-ACCORD 
cohorts and thus was not included in analyses. Separate models were estimated for each 
retention measure. To evaluate whether the association between retention in care and viral 
suppression differs by age group, we included an interaction term between age group and 
each measure of retention; an adjusted Wald test was used to determine if there was 
statistical evidence of interaction. Statistical analyses were performed using Stata 12.1 (Stata 
Corporation, College Station, TX).
Results
A total of 17,044 adults who met study criteria initiated care at NA-ACCORD clinical sites 
between 2006 and 2010. (Table 1) The majority of the patients were <50 years old (15% of 
patients were 18-29 years, 25% were 30-39 years, 34% were 40-49 years), male (81%), and 
of minority race/ethnicity (56%). The predominant HIV risk factor was MSM (40%) 
followed by HET (27%) and IDU (11%). Overall, 89% of patients were retained in care 
according to the NHAS measure, 74% according to the DHHS indicator, 85% did not have a 
6-month gap, and 62% had visits in 3-4 quarters of the year. Fifty-five percent of the sample 
was prescribed ART in their first full calendar year of observation. Among those with 
available viral load data (n=15,378 or 90% of the 17,044 who initiated care), 54% achieved 
viral suppression.
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Figure 1 shows the unadjusted proportions of patients with viral suppression, by age group 
and retention measure. For each measure, three significant (p <0.05) results from chi-
squared tests are clear: (1) the older the individual, the greater the probability of viral 
suppression in both the retained and not retained in care groups; (2) patients who were 
retained in care had a greater probability of viral suppression than those not retained in care, 
but this difference decreased as age groups increased; and (3) the association between 
retention in care and viral suppression was greatest for younger versus older age groups.
Table 2 shows APRs for the joint effect of retention in care on viral suppression at different 
age groups. For each retention measure, the association with viral suppression was 
significant (p <0.05) for only the younger age groups (18-29 years and 30-39 years): NHAS 
measure (APR=1.33 [1.03, 1.70] for 18-29; APR=1.23 [1.01, 1.49] for 30-39), DHHS 
indicator (APR=1.19 [1.02, 1.39] for 18-29; APR=1.23 [1.09, 1.39] for 30-39), 6-month gap 
in care measure (APR=1.28 [1.04,1.57] for 18-29; APR=1.16 [1.01, 1.35] for 30-39), and 3-
month visit constancy (APR=1.36 [1.09, 1.69] for 3 quarters and APR=1.47 [1.18, 1.82] for 
4 quarters for 18-29; APR=1.27 [1.07, 1.50] for 3 quarters and APR=1.41 [1.19, 1.66] for 4 
quarters for 30-39). Pairwise comparisons of APR between the two youngest age groups 
were significant (p <0.05). We did not observe any significant differences in the probability 
of viral suppression for older individuals who were retained versus not retained in care. 
Sensitivity analyses categorizing those with missing viral load data as “not suppressed” 
yielded similar results. (Appendix Table 1)
Appendix Tables 2 and 3 present associations between patient factors and viral suppression. 
In models adjusting for gender, race/ethnicity, HIV transmission risk factor, use of ART, 
first CD4 count, calendar year, cohort, and including a interaction term between age group 
and retention in care, persons with black race/ethnicity (vs. white) and HET risk or IDU risk 
(vs. MSM) were significantly (p <0.05) less likely to achieve viral suppression, regardless of 
the retention measure assessed. Persons on ART and those who entered care in more recent 
years were significantly (p <0.05) more likely to be virally suppressed.
Discussion
This study evaluate the relationship between age, retention in care, and viral suppression, 
and suggests that viral suppression is significantly more prevalent in younger HIV-infected 
adults (18-39 years old) retained in care than in similarly aged persons not retained in care. 
The U.S. Centers for Diseases Control and Prevention estimate that approximately 14,200 
individuals aged 20-29 and 11,200 individuals aged 30-39 were newly infected with HIV in 
2010, representing the highest burden of new HIV infections among all age groups.39 
Retaining younger HIV-infected persons in care may be particularly important to improving 
clinical outcomes and reducing transmission of HIV in this population.40
While older patients were more likely to achieve viral suppression, we demonstrate that the 
effect of retention in care on viral suppression was greatest for patients aged 18-39 
compared to those 40 years and older. This pattern persisted independent of the measure of 
retention utilized. Prior research indicates that younger adults have lower rates of ART 
adherence than older adults.23,24,26 Of 5,090 HIV-infected patients enrolled in a large 
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integrated health care system, patients 50 years or older sustained higher therapy adherence 
(88.9%) than 18-39 (83.7%) and 40-49 years old (85.7%), respectively.26 Among 148 HIV-
infected adults on ART and receiving care in Los Angeles, CA, adherence to HIV therapy 
was significantly higher in older (≥50 years old) versus younger (<50 years old) patients 
(87.5% versus 78.3%, respectively).24 Similarly, a recent systematic review and meta-
analysis noted that older age reduced the risk of ART non-adherence by 27% (relative risk 
0.72, [0.64, 0.82]).25 These studies suggest that differences in ART adherence between older 
and younger adults exist and may mediate the relationships with viral suppression. 
Unfortunately, ART adherence data was unavailable and thus was not included in our 
analyses. Regular clinic attendance may help younger adults comply with HIV treatment and 
achieve viral suppression by providing one-on-one ART education and counseling, tools to 
improve medication adherence (e.g. pillboxes, reminder devices), and access to case 
management and ancillary services to address competing food insecurity, housing, and 
transportation needs.41 These resources may be equally important to maintaining ART 
adherence in older adults.
HIV-related stigma, fear of disclosure, and stress significantly impact the experiences and 
health of people living with HIV.42-44 Some data suggest that younger individuals may 
confront these challenges at higher rates than older adults, while other report no difference 
between age groups.45-48 Among 147 HIV-infected adolescents and young adults aged 
16-29 years living in New York, Los Angeles, and San Francisco, almost all (89%) reported 
perceived stigma (a stigmatized person's fear or anticipation of discrimination and rejection, 
and internal sense of shame) and 64% reported enacted stigma (actual experiences of stigma 
and discrimination) during their lifetime.49 In an analysis exploring the relationship between 
age and patterns of disclosure, younger adults were significantly more likely to fear losing 
their job because of their HIV status than older adults.45 Likewise, among 102 adults living 
with HIV in a large city, individuals ≤50 years old had more social isolation than those >50 
years old.47 Maintaining a continuous relationship with a provider may offer younger adults 
access to resources to better manage HIV-related stigma and barriers to care, which may 
contribute to improved ART adherence and achievement of viral suppression. However, the 
availability and quality of these resources may differ by provider and clinic.
Our finding that the association between retention in care and viral suppression was 
strongest for younger patients does not preclude the possibility that there may be subgroups 
of older individuals for whom retention may be equally or more important to achieving viral 
control and other health outcomes. For example, continuous engagement in care may be key 
to managing comorbid conditions (e.g. diabetes, heart failure) in older people with HIV 
infection.50 Further studies examining these nuances may help in the development of more 
personalized measures of retention in care.
Our analysis has several limitations. First, our data do not reflect visits to multiple providers 
by the same patient. It is possible that patients may switch facilities or providers in the same 
locality, emigrate from the area, or become incarcerated, institutionalized, or hospitalized 
but still be receiving care. Younger adults may be more mobile than older adults, impacting 
engagement in care.51 Second, we measured use of ART and viral suppression, but did not 
specifically assess adherence to HIV treatment. Future studies are warranted to investigate 
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the relationship between ART adherence, age, retention in care, and viral suppression. Third, 
we focused on the first full calendar year in primary HIV care to allow sufficient time to 
observe retention measures. Thus, patients who were linked to outpatient care with less than 
one year of follow-up were excluded; additional research to better understand persons who 
are unable to establish consistent care is warranted.2,52. Fourth, HIV-infected individuals are 
living longer,53 which requires new evaluations of longer-term retention in care and viral 
suppression. Similarly, as HIV therapy, national treatment guidelines, and telehealth 
continue to advance new standards and methods for assessing retention in care will be 
needed. Fifth, our cross-sectional study design precludes inference of causality. Sixth, we 
are limited by the current retention measures in use, which only include primary HIV care 
appointments and do not account for nursing, pharmacy, laboratory, or other types of visits. 
Exclusion of these points of contact with the healthcare system may underestimate retention 
in care. Lastly, while NA-ACCORD constitutes a patient population that is a large 
proportion of and demographically similar to persons living with HIV/AIDS in the U.S.,54 
care sites vary in operations and support services provided, which may impact 
generalizability of our findings.
In summary, we reported that retention in care is more strongly associated with viral 
suppression in younger adults. These results have important implications for the test and 
treat approach to HIV prevention, emphasizing the crucial role retention in care plays in 
supporting viral suppression in younger adults.
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Table 1
Demographic and Clinical Characteristics of the Sample
Characteristic Overall N=17,044 (%)
Age (years)
    18-29 2,560 (15%)
    30-39 4,261 (25%)
    40-49 5,826 (34%)
    50-59 3,259 (19%)
    ≥ 60 1,138 (7%)
Sex
    Male 13,764 (81%)
    Female 3,289 (19%)
Race/Ethnicity
    White 6,244 (37%)
    Black 7,101(42%)
    Hispanic 2,143 (13%)
    Unknown 1,364 (8%)
HIV Risk Factor
    MSM 6,789 (40%)
    Heterosexual 4,591 (27%)
    IDU 1,850 (11%)
    Unknown 3,409 (22%)
First CD4 Count in Year
    < 350 cell/mm3 7,511 (44%)
    350-499 cell/mm3 3,669 (22%)
    ≥500 cell/mm3 4,321 (25%)
    Missing 1,534 (9%)
Use of ART in Year
    No 7,590 (45%)
    Yes 9,454 (55%)
Calendar Year
    2006 3,719 (22%)
    2007 3,510 (21%)
    2008 3,611 (21%)
    2009 3,346 (20%)
    2010 2,858 (16%)
NHAS Retention Measure
    Not Retained 1,846 (11%)
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Characteristic Overall N=17,044 (%)
    Retained 15,198 (89%)
DHHS Retention Indicator
    Not Retained 4,473 (26%)
    Retained 12,571 (74%)
6-Month Gap
    Yes (Not Retained) 2,563 (15%)
    No (Retained) 14,481 (85%)
3-Month Visit Constancy
    1 2,901 (17%)
    2 3,586 (21%)
    3 4,806 (28%)
    4 5,751 (34%)
Viral Suppression
    No 7,119 (42%)
    Yes 8,259 (48%)
    Missing 1,666 (10%)
Abbreviations: ART, antiretroviral therapy; DHHS, Department of Health and Human Services; HET, heterosexual transmission; HIV, human 
immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men; NHAS, National HIV/AIDS Strategy.
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Table 2
Association between Retention in Care Measures and Viral Suppression by Age Group
Retention Measure Age Group
18-29 years APR 
(95% CI)
30-39 years APR 
(95% CI)
40-49 years APR 
(95% CI)
50-59 years APR 
(95% CI)
≥ 60 years APR 
(95% CI)
NHAS Measure
    Not Retained 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref]
    Retained 1.33 (1.03-1.70) 1.23 (1.01-1.49) 1.06 (0.90-1.22) 0.92 (0.75-1.13) 0.99 (0.63-1.56)
DHHS Indicator
    Not Retained 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref]
    Retained 1.19 (1.02-1.39) 1.23 (1.09-1.39) 1.08 (0.97-1.19) 0.99 (0.87-1.14) 0.97 (0.75-1.25)
6-Month Gap in Care
    Yes (Not Retained) 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref]
    No (Retained) 1.28 (1.04-1.57) 1.16 (1.01-1.35) 1.12 (0.99-1.27) 0.96 (0.81-1.14) 1.09 (0.74-1.60)
3-Month Visit Constancy
    1 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref] 1.00 [Ref]
    2 1.22 (0.97-1.55) 1.16 (0.97-1.40) 0.98 (0.85-1.14) 1.02 (0.83-1.25) 1.01 (0.67-1.52)
    3 1.36 (1.09-1.69) 1.27 (1.07-1.50) 1.12 (0.98-1.29) 1.00 (0.83-1.20) 0.95 (0.65-1.37)
    4 1.47 (1.18-1.82) 1.41 (1.19-1.66) 1.13 (0.99-1.29) 1.03 (0.86-1.23) 1.01 (0.71-1.45)
Abbreviations: APR, adjusted prevalence ratio; CI, confidence interval; DHHS, Department of Health and Human Services; NHAS, National 
HIV/AIDS Strategy.
Models included an interaction between retention measure and age group, and adjusted for sex, race/ethnicity, HIV risk factor, first CD4 cell count 
in the year, use of ART for >6 months during the year, calendar year, and cohort as time-fixed covariates.
Bold signifies adjusted prevalence ratios with p-vale <0.05.
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